Foghorn Therapeutics Inc. 8-K Summary
Business Context and Reporting Period
Foghorn Therapeutics Inc. filed a Current Report on Form 8-K dated June 21, 2022, reporting the results of its 2022 Annual Meeting of Stockholders. The company is a Delaware corporation headquartered in Cambridge, Massachusetts, and its common stock trades on Nasdaq under the symbol FHTX.
Financial Metrics and Liquidity
This filing does not provide revenue, profitability, cash flow, margins, debt, liquidity, or other operating and financial metrics.
Material Changes and Meeting Results
- Stockholders elected Adrian Gottschalk, Adam Koppel, M.D., Ph.D., and Ian F. Smith as Class II directors, each for a three-year term.
- Votes present or represented totaled 31,121,419.30 shares out of 41,467,808 shares entitled to vote.
- There were 2,246,272 broker non-votes on the director elections.
- Stockholders ratified Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022.
- The auditor ratification received 31,108,691.29 votes for, 4,028 against, and 8,700 abstentions, with no broker non-votes.
Guidance, Outlook, Risks, and Unusual Items
The filing provides no financial guidance, business outlook, management commentary, new risk disclosures, contingencies, or unusual financial items. It reports routine annual-meeting governance matters only.
Important Facts for Investors to Verify
- Confirm the elected directors’ terms and committee assignments in subsequent company disclosures.
- Review the company’s separate periodic filings for financial performance, cash runway, debt, clinical-development spending, and liquidity.
- Review the proxy statement filed April 29, 2022 for detailed proposal information and governance matters.
- Note that the filing was signed June 23, 2022, although the reported annual meeting occurred June 21, 2022.